Xeris Biopharma Holdings, Inc. — Form 8-K Summary
Business Context and Reporting Period
Xeris Biopharma Holdings, Inc. filed a Current Report on Form 8-K dated October 16, 2023. The filing reports a Regulation FD disclosure concerning updated 2023 cash and revenue guidance. The company’s common stock trades on Nasdaq under the symbol XERS.
Financial Metrics
The filing text provided does not include reported revenue, profit, cash flow, margins, debt, liquidity balances, or other historical financial metrics. It states only that the company updated its cash and revenue guidance and raised its year-end 2023 cash guidance.
Material Changes Versus the Prior Comparable Period
No period-over-period financial results or comparable-period amounts are provided. The material change disclosed is an update to 2023 guidance, including an increase to projected year-end cash.
Guidance, Outlook, Risks, and Unusual Items
- The company announced updated 2023 cash and revenue guidance.
- Year-end 2023 cash guidance was raised.
- The specific guidance ranges, assumptions, and reasons for the updates are not included in the supplied filing text.
- The disclosure was furnished under Item 7.01 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings except where expressly stated.
- The company stated that it undertakes no obligation to update, supplement, or amend the materials.
Key Facts for Investor Verification
- Review Exhibit 99.1 for the exact updated revenue guidance and year-end cash guidance.
- Verify the prior guidance ranges and the magnitude of the cash guidance increase.
- Assess management’s stated assumptions, operating drivers, and any conditions or risks accompanying the revised outlook.
- Confirm whether the guidance is presented as a range and whether it excludes or includes specific cash uses, financing activities, or acquisition-related items.